The distinguishing results from different breast cancer subtypes reveals that the prognostic value of FFAR4 might only apply to HRPBC patients (Luminal A, Luminal B HER2 negative and Luminal B HER2 positive). Here, ERBB2 is linked to breast carcinoma.